Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Key Highlights
- ➤Profound Medical and Telix enter co-education agreement for PSMA-informed prostate care
- ➤Collaboration expands Profound’s access to urologists through Telix’s strategic partnership
- ➤Profound plans PSMA-PET–MR image fusion in a future TULSA-PRO software release
- ➤PSMA-PET may improve TULSA-PRO patient selection and customized treatment planning
Expert Statements
Arun Menawat, Chief Executive Officer and Chairman of Profound Medical
“This agreement strengthens our relationship with an important strategic participant in the prostate cancer ecosystem and increases our access to urologists across the U.S. and internationally”
Arun Menawat, Chief Executive Officer and Chairman of Profound Medical
“By bringing together advanced molecular imaging and incisionless, MRI-guided therapy, we see an opportunity to support broader market development, enhance clinical education and increase awareness of the complementary value of our respective technologies.”
Arun Menawat, Chief Executive Officer and Chairman of Profound Medical
“Over time, we also believe the incorporation of Telix’s PSMA-PET capabilities within TULSA-PRO centers could strengthen their clinical and economic value proposition, including by supporting more informed treatment decisions and potentially enhancing return on investment.”
Kevin Richardson, CEO of Telix Precision Medicine
“As new technologies continue to transform prostate cancer care, clinical education is essential to helping physicians understand how PSMA-PET imaging can inform patient selection and treatment planning across a range of minimally invasive and image-guided approaches”
Kevin Richardson, CEO of Telix Precision Medicine
“Through this collaboration with Profound, we aim to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy and support more personalized care for patients.”
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“Approximately 85% of prostate cancers are multifocal, involving two or more distinct index or satellite lesions in different areas of the prostate, while approximately 15% are unifocal, with a single tumor site(2)”
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“A significant strategic advantage of TULSA-PRO is its ability to support a spectrum of customized, regional ablation plans — from whole-gland, to focal, and everything in between.”
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“We believe PSMA-PET has the potential to enhance multiple stages of the TULSA Procedure, including patient selection, treatment planning, determination of ablation extent and margin definition.”
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“Molecular imaging may help identify the approximately 15-25% of patients who are candidates for focal ablation as well as certain higher-risk patients who may remain suitable for whole-gland ablation.”
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“Perhaps more significantly still, it may help physicians customize the treatment strategy to each patient’s individual disease characteristics.”
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO(®)
Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans
Get started
Create a free account to read the full story.